Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SN132D in breast and pancreatic cancer
NCT04080024Phase 1Completed
- Sponsor
- Spago Nanomedical AB
- Start
- Aug 2019
- Primary completion
- Nov 2022
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pegfosimer manganese in breast cancer and pancreatic cancer (PC), sponsored by Spago Nanomedical AB. Primary endpoint: Number of treatment related adverse events. Started Aug 2019; status: completed.
02
Drugs
pegfosimer manganese
03
Conditions
breast cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04080024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04080024.